All News

Patients with stage IIA to IIIA NSCLC identified as low risk per LAMPAD criteria may be candidates for treatment de-escalation with nivolumab.

ZW191 is currently under evaluation in a phase 1 trial that has already demonstrated activity among patients with platinum-resistant ovarian cancer.

ONCOLOGY has identified FDA approvals that have affected the oncology treatment paradigm over the last 40 years.

Julian Hong, MD, MS, offered strategies for providing mental health services into routine workflows for patients undergoing anti-cancer treatment.

About 50% to 60% of Lambert-Eaton myasthenic syndrome cases occur secondary to a malignancy, most commonly small cell lung cancer, and 3% of patients with SCLC have LEMS.

Data from the phase 3 TOP trial support a potential molecular risk–guided treatment strategy for EGFR-mutant advanced NSCLC.

Soft tissue sarcomas are a rare but heterogeneous group of tumors accounting for less than 1% of all cancers.

Linda E. Carlson, PhD, RPsych, asserted mindfulness programs have strong evidence in managing psychosocial symptoms, but require increasing access for use.

Berzosertib plus cisplatin and radiotherapy did not meet the preliminary efficacy end point of complete response rate in this head and neck cancer group.

Data from the Lung-Care Project showed that non–high-risk patients experienced better survival and curative potential through early detection.

In the phase 3 KEYNOTE-590 trial, the PD-L1 IHC 22C3 pharmDx (Code SK006) companion diagnostic was used to evaluate PD-L1 status in tumor specimens.

Today the patient-physician relationship that Pergament et al outlined in 1999 is even more prevalent, driven by the rapid development, use, and uptake of social media across all oncology fronts.

Linda Carlson, PhD, RPsych, explored the shift from efficacy to implementation in integrative oncology, emphasizing behavioral interventions.

Yesne Alici, MD, discussed cancer-related fatigue and cognitive impairment and addressed sleep disturbances and AEs such as anemia to improve outcomes.

Low-grade toxicity related to durvalumab in the ASTEROID trial was common, which mostly consisted of skin reactions, pruritus, and fatigue.

Clinically relevant variants were detected in 64% of samples, with negative results informing response or ruling out central nervous system lymphomas.

Adding atezolizumab to adjuvant FOLFOX significantly improves disease-free survival for patients with stage III mismatch repair-deficient colon cancer.

Investigators are currently evaluating treatment with TRI-611 among patients with ALK-positive non–small cell lung cancer in a phase 1/2 trial.

It is a good option to move to BCMA-directed therapy for patients with multiple myeloma after an initial relapse, said María-Victoria Mateos, MD, PhD.

Experts detail presentations that may influence the standard of care across different bladder, kidney, and prostate cancer populations.

Investigators highlighted that emotional and cognitive consequences of beliefs were primarily negative among caregivers of children with cancer.

PET-negative soft tissue disease may prompt a rebiopsy, particularly in enriching for treatment-emergent neuroendocrine prostate cancers.

Updated data demonstrated a 14.7-month OS benefit when adding IMNN-001 to neoadjuvant chemotherapy in patients with newly diagnosed ovarian cancer.

The FDA previously approved the gene therapy as a treatment for high-risk BCG-unresponsive NMIBC with CIS plus or minus papillary tumors in December 2022.

An intern doctor at Al-Sabah Children’s Hospital sheds light on health care delivery gaps in a resource-limited setting.

Data from the SAMSON-II trial showed comparable PFS and OS outcomes with HD204 and reference bevacizumab among patients with nonsquamous NSCLC.

Data from the ROSELLA trial support the approval of relacorilant plus nab-paclitaxel in this ovarian cancer population.

Yan Leyfman, MD, reflected on resilience and hope in the face of cancer, recounting a 37-year-old diagnosed with stage IV colorectal cancer followed by HIV.

Rahul Aggarwal, MD, discussed the high unmet needs of neuroendocrine prostate cancer, highlighting biopsy triggers, genomic markers, and emerging targets.